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BiasHigh incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-
valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed else-
where. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in dif-
ferent countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of
hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and
Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era.
In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998–99) was observed
compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpa-
tient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by
hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospi-
talised IPD in US when compared to other countries.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
The first pneumococcal conjugate vaccine against the seven
most prevalent pneumococcal serotypes causing invasive disease
in children (PCV7) was licensed in The United States in 2000 and
in Europe in 2001. The US was the first to introduce PCV7 into
the childhood vaccination programme in 2000, while other coun-
tries followed suit several years later. Higher-valent PCVs, PCV10
and PCV13, were licensed in 2009–2010, and PCV7 programs were
subsequently replaced with one of these vaccines. In addition tothe PCVs used, the infant vaccination schedules, number of doses,
and use of catch-up programmes among older children as a part
of the PCV introduction differed between the countries (Table 1)
[1–5].
The steep reduction in overall invasive pneumococcal disease
(IPD) following the PCV7 introduction in the US was remarkable
[6], not only in the vaccinated target cohort of children but also
in unvaccinated older children and adults because of the indirect
(herd) effect through reduction in vaccine-type pneumococcal car-
riage in children and reduced onward transmission to others. The
success of the US program encouraged other countries to introduce
PCV in their infant vaccination programmes. Other countries, how-
ever, have reported less remarkable reductions in IPD incidence,
mostly because of more rapid emergence of IPD due to non-PCV
serotypes as a result of the replacement phenomenon [2–5,7].
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1552the other countries have remained largely unknown, yet several
hypotheses have been proposed: differences in pre-vaccination
serotype distribution, environmental and sociologic factors influ-
encing transmission and replacement, antimicrobial use influenc-
ing the emergence of antibiotic-resistant clones, and variation in
diagnostic and hospitalisation practices [8].
One major difference in the pre-PCV era was the higher IPD inci-
dence in the US compared to many other countries and inclusion of
a high proportion of outpatient cases without hospitalisation in the
Active Bacterial Core (ABC) IPD surveillance [6,9]. The high propor-
tion of non-hospitalised IPD cases diminished with time since
PCV7 introduction, with most reported cases in recent years being
hospitalised [6,10–11]. To date, a formal analysis comparing PCV
impact on hospitalised and outpatient IPD cases in different set-
tings has been missing.
Therefore, we reanalysed the published data in children to
explore impact of PCV7 and higher-valent PCVs in the US on hospi-
talised and outpatient IPD incidence separately, and compared
those to results from countries with well-established surveillance
systems including England & Wales, Finland, The Netherlands
and Quebec (Canada).2. Methods
We performed a descriptive analysis for the surveillance data
published previously or specifically extracted the data for the pre-
sent analysis. Details of the PCV vaccination programmes in differ-
ent countries are presented in Table 1 [1–5].
US CDC researchers were invited as co-authors, but they
declined and thus we had no access to the ABC surveillance indi-
vidual data. Therefore, the US incidence rates were extracted from
the public website for 1998–2015 [12].
The IPD surveillance is nationwide in England and Wales, Que-
bec (for children) and Finland. Sentinel surveillance is used in the
Netherlands (9 sites, approximately 25% of the Netherlands popu-
lation) and in the US ABC surveillance (currently 10 sites, approx-
imately 10% of the US population).
We extracted the proportions of hospitalised and outpatient IPD
cases in children less than 5 years of age from the national dataset
for Quebec and Finland. Hospitalisation was defined as an inpatient
admission into a hospital ward. Data for the US [1,6,10–11] were
extracted from the published literature as reported (no definitions
given). In England and Wales and The Netherlands, blood cultures,
especially in children, are nearly always only performed in the hos-
pital setting [4,9,13].
We divided the IPD incidence into hospitalised and outpatient
categories for the US-ABC data. We assumed similar vaccine/non-
vaccine serotype distributions in hospitalised and outpatient cate-
gories in the absence of detailed published data for the post-PCV13
era, and therefore, used adjusted incidence rates for hospitalised
and outpatient non-PCV serotypes, based on the overall distribu-
tion of annual hospitalised and outpatient categories. Analysis of
data reported from US ABC surveillance [10], however, allowed
comparison of the serotype distribution between PCV7 and non-
PCV7 serotypes in the pre- and post-PCV7 era. This showed similar
proportions of IPD cases due to non-PCV7 serotypes in hospitalised
and non-hospitalised cases (19% and 16%, respectively) in the pre-
PCV7 baseline period (1998–1999) and in the post-PCV7 period
from 2006 to 2007 (98% and 99%, respectively). As the proportions
of hospitalised IPD cases in the other countries except the US were
stable without any trends, we report for those overall IPD only.
Using a before-after design, we compared the average incidence
during the two years prior to first PCV introduction up until years 5
and 6 (average of either calendar years or epidemiological years as
available for each surveillance region) after the extended-valency
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ratios (IRR) by dividing the post-PCV incidence rate by the pre-
PCV incidence rate.3. Results
Before PCV introduction, only 32% of IPD cases in children
below 5 years were hospitalised in the US but this proportion
increased to 69% after PCV introduction by 2012. In contrast, 67
to 99% of childhood IPD cases were hospitalised in the other coun-
tries and this proportion remained relatively constant over the
surveillance period (Fig. 1, Supplement Figure 1).
IPD incidence prior to PCV introduction and up until 5 to 6 years
after introduction of higher-valent PCVs (PCV10/PCV13), with their
respective IRRs are shown in Table 1. While the decreases in overall
IPD were similar for other countries, the results for the US differed.
When the US results were stratified by hospitalisation status, the
results for hospitalised IPD cases were consistent with the results
of the other countries (Table 1, Fig. 2).
The US ABC results diverged especially for replacement disease
due to non-PCV serotypes, with a greater than 2-fold increase in
the adjusted incidence of hospitalised cases of IPD due to non-
PCV13 serotypes compared to 51% reduction in outpatient IPD
cases due to non-PCV13 serotypes (Table 1, Fig. 2). The incidence
and trends in replacement disease due to non-PCV13 serotypes
that was observed among hospitalised IPD cases in US children
was similar to that observed for the other countries (Fig. 2).4. Discussion
Our analysis shows that the impact of PCVs on overall IPD inci-
dence in hospitalised children younger than 5 years was similar in
the US ABC surveillance compared to the other countries in North
America and Europe. Strikingly, in the US the relative changes for
non-PCV IPD representing replacement disease diverged between
hospitalised and outpatient cases. This differential impact would
be consistent with a reduction in routine blood cultures taken from
young children in the emergency departments and outpatient clin-
ics during the post-PCV era; this change in diagnostic practice has
been suggested in many published reports since PCV introduction
in the US [16–18], yet has not been formally reported in any impact
evaluation.Fig. 1. Proportion of hospitalised cases out of all reported IPD cases in the US ABC survei
1553Another possible reason for the differential reduction in hospi-
talised and outpatient IPD cases within the US ABC surveillance
could be due to differences in serotype distribution between these
two patient groups, i.e. if IPD cases among outpatients were more
commonly caused by vaccine serotypes. However, this does not
seem be the case as, in children younger than 5 years of age, 84%
of outpatient IPD cases in the pre-vaccine era were due to PCV7
types, compared to 81% of the hospitalised IPD cases in the US
(Ref. 10, Table 3) [10].
The 3-fold higher incidence of IPD prior to PCV introduction in
the US compared to most other countries is likely due to differ-
ences in detection and diagnosis of IPD, especially taking blood cul-
tures from febrile children in outpatient settings. Outside the US,
the blood cultures are mostly taken in inpatient settings. In the
present study, most laboratory-confirmed IPD cases were hospi-
talised; 97–98% in the Netherlands [12], 86–95% in Finland, 67–
91% in Quebec (Supplement Figure) and almost all cases in England
and Wales. Obtaining blood cultures in the outpatient setting
would increase the number of laboratory-confirmed IPD cases
(i.e. true positives), which would not be included in routine IPD
surveillance in the other countries. Finnish vaccine probe studies
have shown that in addition to laboratory-confirmed IPD, PCV
can prevent a considerably higher disease burden of clinically sus-
pected IPD cases in which blood cultures remained negative [19–
20]. Thus, the true incidence of IPD is higher than estimated trough
most laboratory-based surveillance systems. The estimation of the
relative impact of any vaccination programme is not biased by low
sensitivity of case detection (e.g. by exclusion of cases presenting
or being treated outside the hospital setting) as long as the situa-
tion remains stable. However, any changes in case ascertainment
during the vaccine evaluation period (e.g. reduced blood culturing
in the outpatient setting) can cause a differential bias and distort
the evaluation.
Ecological before/after studies are particularly vulnerable to dif-
ferent sources of bias. Regarding the evaluation of PCV impact, dif-
ferences in the IPD reduction after PCV introduction and the degree
of replacement disease may be due to different serotype distribu-
tions during the pre-vaccination era including the contribution of
vaccine-preventable serotypes to overall IPD, contemporaneous
implementation of other interventions such as influenza vaccina-
tion, changes in hospitalisation practices and/or outpatient man-
agement, changes in severity of clinical disease leading to
differential presentation to primary care or the hospital, or changesllance by calendar year in children and adults based on published reports [6,10–11].
Fig. 2. Incidence of all IPD in children below 5 years of age in US (panel A) and in Quebec, Canada and European countries (panel B) before and after infant PCV introduction*,
panels C and D for non-PCV serotypes.
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other risk factors. Evaluation of vaccine impact is also complicated
by changes in transmission dynamics over time and secular or geo-
graphic trends within pneumococcal serotypes or clonal lineages
that may be unrelated (e.g. changes in serotype 1 IPD prior to
PCV13 introduction) [8] or related (e.g. selection pressure) to the
immunisation programme. These can be partially controlled by
using trend analyses, external controls, or a combination of these.
A limitation of this analysis includes the lack of data for IPD
cases in the ABC surveillance stratified by inpatient/outpatient sta-
tus and serotype grouping. We therefore assumed similar propor-
tions of vaccine serotypes causing IPD in the outpatient and
inpatient cases in the US. One US study, which did report IPD cases
by serotype grouping and inpatient/outpatients status for the pre
and post-PCV7 era, showed a significant increase in IPD due to
non-PCV7 serotypes for hospitalised cases from 6.1 to 12.3 per
100 000 person-years but a non-significant decrease in outpatient
NVT IPD cases (from 10.7 to 9.7) by 2006–2007 [10]. Our results
are in line with these, taking into account that we reported changes
over a longer time-period when further reductions in the propor-
tion of outpatient IPD cases were reported in the ABC surveillance.
The sole aim of the current analysis was to compare the US-ABC
hospitalised IPD cases to overall IPD for the other countries, where
most IPD cases are routinely hospitalised; therefore, differences in
the vaccination programmes, schedules, vaccines uptake or other
surveillance factors between the different countries were not con-
sidered in detail. For example, increase in non-PCV-types (replace-
ment disease) seemed lower in the PCV10 countries Netherlands
and Finland (Table 1), probably due to the cross-protection against
19A and 6A, here included as non-PCV10 types.
The US-ABC surveillance has also reported a divergent indirect
impact of the childhood PCV programme on older adults aged
65 years or more. While disease replacement with non-PCV sero-
types increased 2–4-fold in other countries, the increase reported
by US-ABC has been minimal [1,8]. The reason for this discrepancy
is not the same as in the children, since nearly all IPD cases among1554older adults were routinely hospitalised prior to vaccine introduc-
tion (Fig. 1). However, this difference could be explained by
changes in blood culture or hospital admission practices within
the ABC surveillance. The published data [10] suggest changes
mainly in the clinical syndrome of bacteraemia without a focus;
among 65+ year-olds, non-PCV type invasive pneumonia incidence
increased significantly (from 18.5 to 26.6/100 000) as did pneumo-
coccal meningitis (from 1.1 to 1.4/100 000) while bacteraemia
without focus decreased slightly (from 6.5 to 5.9) [10].
In conclusion, we suggest that the reduction in outpatient blood
culture practice after the PCV introduction in US has contributed to
the discordant results observed in the US ABC surveillance data
compared to other high-income countries for IPD in children.
Therefore, for scientific reports and for cross-country comparison
purposes, the analysis of IPD surveillance data should be stratified
by hospitalisation status.Authors contributions
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